Find a Clinical Trial

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.

Purpose of Study

This is an open-label, multicenter, global Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031 in patients with selected relapsed or refractory (R/R) malignancies. The study will be conducted as separate Phase 2, single arm substudies for each of the indications below:

Extranodal NK/T-cell lymphoma (ENKTL)
Peripheral T-cell lymphomas (PTCL)
Diffuse large B-cell lymphoma (DLBCL) with PD-L1 gene translocation, copy gain, amplification, polysomy detectable by a fluorescence in situ hybridization (FISH) assay or Epstein-Barr virus positivity (EBV+) as assessed by EBV-encoded small RNA (EBER) testing
Biliary tract cancers (BTC) (intrahepatic cholangiocarcinoma), extrahepatic cholangiocarcinoma or gallbladder cancer)

All participants will receive the study intervention, STI-3031.

Eligibility

Age:
18 +
Sex:
All

Key Inclusion / Exclusion Criteria

Inclusion Criteria:

Documented histologically confirmed diagnoses of Extranodal NK/T-cell lymphoma, Peripheral T-cell lymphoma, Diffuse Large B-cell lymphoma (with a PD-L1 gene abnormality or Epstein-Barr virus positivity, or biliary tract cancer.

Prior treatment:

Extranodal NK/T-cell lymphoma: Must have received at least 1 previous line of systemic therapy including an asparaginase-based regimen.
Peripheral T-cell lymphoma: must have received at least 1 previous line of systemic multi-agent chemotherapy. Participants with anaplastic large cell lymphoma (ALCL) must have received brentuximab vedotin
Diffuse Large B-cell lymphoma: Must have received at least 2 previous lines of systemic therapy including an anti-CD20 antibody
Biliary Tract Cancer: Must have received at least 1 previous line of systemic therapy including gemcitabine with or without platinum
Documented disease progression during or after the last therapy
If not previously treated with transplant, Investigator considers the participant ineligible for transplant
Measurable disease
Adult age (as defined by respective country) at time of signing informed consent form (ICF)
Must be able to understand the nature of the study and provide a signed and dated, written ICF prior to any study-specific procedures, sample collections and analyses
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment and radiopharmaceuticals are permitted if more than 8 weeks have elapsed since the end of treatment
At least 14 days or 5 half-lives must have elapsed since the last chemotherapy, immunotherapy, biological or investigational therapy, and have recovered from toxicities associated with such treatment to < Grade 2 Adequate hematologic, renal and hepatic function Females of childbearing potential (FCBP) must agree to use a reliable form of contraceptive during the study treatment period and for at least 90 days following the last dose of study intervention Male participants must agree to use barrier contraception (i.e., condoms) for the duration of the study and for at least 90 days after the last dose of study intervention Predicted life expectancy of at least 16 weeks Exclusion

Exclusion Criteria:

Current participation in another therapeutic clinical trial Prior treatment with an anti-PD-L1 or anti-PD-1 antibody Patients with symptomatic central nervous system (CNS) metastases unless considered adequately treated and controlled for at least 2 weeks Prior hematopoietic stem cell transplantation History of other previous cancer that would interfere with the determination of safety or efficacy Any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for participants with vitiligo, hormone replacement therapy for stable thyroid diseases and Type 1 diabetes mellitus Apparent active or latent tuberculosis (TB) infection Seropositive for or have active infection with hepatitis C virus (HCV), unless HCV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy Seropositive for or have active viral infection with hepatitis B virus (HBV), unless HBV viral load is below the limit of quantification and participant is on concurrent viral suppressive therapy Seropositive for or active viral infection with HIV, unless the following are met: CD4+ T-cell (CD4+) counts ≥ 350 cells/uL; and Participant has been on established antiretroviral therapy (ART) for at least 4 weeks prior to screening and have HIV viral load < 400 copies/mL; and Participant has not had acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the past 12 months prior to screening Active infection (viral, bacterial, or fungal) requiring intravenous (IV) systemic therapy within 14 days Evidence of bleeding diathesis or coagulopathy. Significant proteinuria Conditions requiring chronic steroid use (> 10 mg/day of prednisone or equivalent).
Recent history of attenuated viral vaccination within 30 days prior to the first dose of study intervention
Herbal preparations/medications are not allowed throughout the treatment period unless first discussed with and approved by the Medical Monitor
History of severe hypersensitivity reactions to other monoclonal antibodies or known hypersensitivity to the study intervention or its excipients.
Known current drug or alcohol abuse
Major surgical procedures ≤ 28 days prior to the first dose of study intervention, or minor surgical procedures ≤7 days prior to the first dose of study intervention
Pregnant or lactating

Any of the following cardiac diseases currently or within the last 6 months:

QT interval corrected using Fridericia’s formula >450 milliseconds in men and > 470 milliseconds in women (up to 480 milliseconds may be allowed after discussion between the Investigator and the Medical Monitor).
Left Ventricular Ejection Fraction (LVEF) <45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) Unstable angina pectoris Congestive heart failure (New York Heart Association ≥ Grade 2) Acute myocardial infarction Clinically significant conduction abnormality not controlled with pacemaker or medication Significant ventricular or supraventricular arrhythmias (Participants with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible.) Underlying medical conditions that, in the opinion of the investigator and/or medical monitor, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results

Conditions:

Cancer

Status:

Not yet recruiting

Phase:

Phase 2

Study ID

NCT03999658

Read Detailed Summary

Start Date / End Date:

01/05/2022 -

Enrollment:

220

Full Details:

https://clinicaltrials.gov/ct2/show/NCT03999658

SELECT wp_posts.* FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) INNER JOIN wp_postmeta ON ( wp_posts.ID = wp_postmeta.post_id ) WHERE 1=1 AND ( wp_term_relationships.term_taxonomy_id IN (21) ) AND ( ( wp_postmeta.meta_key = 'study_ctid' AND wp_postmeta.meta_value = 'NCT03999658' ) ) AND ((wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled'))) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC /* From [sorrentotherapeutics.com/study/a-study-of-sti-3031-an-anti-pd-l1-antibody-in-patients-with-selected-relapsed-refractory-malignancies/] in [/nas/content/live/jshi/wp-content/themes/sorrento/single-study.php:255] */